Panelli Danielle M, Gladish Nicole, Perlman Nicola C, Leonard Stephanie A, Chueh Jane, Gotlib Ian H, Cardenas Andres, Bianco Katherine
Division of Maternal-Fetal Medicine and Obstetrics, Department of Obstetrics and Gynecology, the Department of Epidemiology and Population Health, and the Department of Psychology, Stanford University, Stanford, California.
Obstet Gynecol. 2025 Jul 10. doi: 10.1097/AOG.0000000000006000.
To understand the relationship between pregnancy and epigenetic aging estimated by DNA methylation "clocks," which offers a molecular measure of biologic aging.
This was a prospective cohort study of nulliparous women (age 18-50 years) seeking obstetric (pregnant 10-14 weeks) or gynecologic (nonpregnant) care in 2020-2021. Blood was collected at enrollment (time 1) and postpartum day 1 (pregnant, time 2) or 7 months later (nonpregnant, time 2). Epigenetic age was measured with 11 established clocks from Illumina EPIC 2 arrays. Within-person changes in epigenetic age were compared with mixed-effects linear regression models adjusted for confounders and interval duration (days). Results were scaled per 200-day interval. P values were corrected for multiple testing. Multivariable logistic regression explored associations between first-trimester epigenetic age and a composite of potentially immune-mediated complications (hypertensive disorders, gestational diabetes mellitus, preterm birth before 37 weeks of gestation, and small-for-gestational-age birth weight) adjusted for age and body mass index (BMI) higher than 30 at time 1.
In total, 75 women enrolled; 45 (60.0%) were pregnant, and 61 (81.3%) completed the study. Pregnant women exhibited significant within-person epigenetic age acceleration compared with nonpregnant women in six clocks (Hannum, PhenoAge, GrimAge, GrimAge2, Stem Cell Division, DunedinPACE). Additional epigenetic age acceleration per 200 days in the pregnant cohort ranged from 1.58 years (Hannum, 95% CI, 0.45-2.72, P=.01) to 5.28 years (PhenoAge, 95% CI, 2.97-7.61, P<.01). Each additional year of first-trimester GrimAge2 increased odds of the composite of pregnancy complications by 36% (adjusted odds ratio [aOR] 1.36, 95% CI, 1.01-1.84), while chronologic age (in continuous years) showed no association (aOR 1.00, 95% CI, 0.83-1.21).
Pregnancy accelerated within-person epigenetic aging by up to 5.3 years. Older first-trimester GrimAge2, but not chronologic age, was associated with a composite of pregnancy complications. These findings suggest that gestation may influence biologic aging and support further investigation into epigenetic age as a potential marker of pregnancy health.
了解妊娠与通过DNA甲基化“时钟”估计的表观遗传衰老之间的关系,该“时钟”提供了一种生物衰老的分子测量方法。
这是一项对2020 - 2021年寻求产科(怀孕10 - 14周)或妇科(未怀孕)护理的未生育女性(年龄18 - 50岁)进行的前瞻性队列研究。在入组时(时间1)和产后第1天(怀孕,时间2)或7个月后(未怀孕,时间2)采集血液。使用来自Illumina EPIC 2阵列的11个既定时钟测量表观遗传年龄。通过针对混杂因素和间隔持续时间(天数)进行调整的混合效应线性回归模型比较表观遗传年龄的个体内变化。结果按每200天间隔进行缩放。对多重检验进行P值校正。多变量逻辑回归探讨了孕早期表观遗传年龄与潜在免疫介导并发症(高血压疾病、妊娠期糖尿病、妊娠37周前早产和小于胎龄出生体重)的综合指标之间的关联,并对时间1时年龄和体重指数(BMI)高于30进行了调整。
总共75名女性入组;45名(60.0%)怀孕,61名(81.3%)完成了研究。与未怀孕女性相比,怀孕女性在六个时钟(汉努姆、表型年龄、 GrimAge、GrimAge2、干细胞分裂、达尼丁PACE)中表现出显著的个体内表观遗传年龄加速。怀孕队列中每200天额外的表观遗传年龄加速范围为1.58岁(汉努姆,95%置信区间,0.45 - 2.72,P = 0.01)至5.28岁(表型年龄,95%置信区间,2.97 - 7.61,P < 0.01)。孕早期GrimAge2每增加一岁,妊娠并发症综合指标的几率增加36%(调整后的优势比[aOR] 1.36,95%置信区间,1.01 - 1.84),而实际年龄(以连续年计)则无关联(aOR 1.00,95%置信区间,0.83 - 1.21)。
妊娠使个体内表观遗传衰老加速高达5.3岁。孕早期较高的GrimAge2,而非实际年龄,与妊娠并发症的综合指标相关。这些发现表明妊娠可能影响生物衰老,并支持进一步研究表观遗传年龄作为妊娠健康潜在标志物的可能性。